Table II.
ORs and 95% CIs for biliary tract cancers and stones in relation to selected genetic variants
| Gene/variants | Controlsa | Biliary tract cancers | Biliary stones | ||||||||||
| Gallbladder (n = 237) | Bile duct (n = 127) | Ampulla of Vater (n = 47) | Gallbladder (n = 673) | Bile duct (n = 222 | |||||||||
| N1 | N2 | N3 | n | OR (95% CI) | n | OR (95% CI) | n | OR (95% CI) | n | OR (95% CI) | n | OR (95% CI) | |
| RXR-α G70A (rs1536475) | |||||||||||||
| GG | 443 | 414 | 334 | 135 | 1.00 | 74 | 1.00 | 27 | 1.00 | 385 | 1.00 | 123 | 1.00 |
| GA | 282 | 266 | 212 | 90 | 1.04 (0.76–1.42) | 44 | 0.93 (0.62–1.39) | 16 | 0.93 (0.49–1.76) | 234 | 0.92 (0.72–1.17) | 78 | 1.02 (0.73–1.43) |
| AA | 51 | 47 | 37 | 10 | 0.65 (0.32–1.33) | 6 | 0.71 (0.29–1.71) | 3 | — | 43 | 0.91 (0.57–1.46) | 14 | 0.99 (0.51–1.90) |
| P for trend | 0.55 | 0.46 | 0.89 | 0.49 | 0.95 | ||||||||
| RXR-α A-27G (rs1805343) | |||||||||||||
| AA | 317 | 298 | 239 | 98 | 1.00 | 51 | 1.00 | 21 | 1.00 | 268 | 1.00 | 94 | 1.00 |
| GA | 351 | 329 | 266 | 107 | 1.00 (0.73–1.37) | 53 | 0.94 (0.62–1.43) | 21 | 0.93 (0.50–1.73) | 307 | 0.98 (0.77–1.26) | 94 | 0.89 (0.64–1.25) |
| GG | 105 | 98 | 76 | 26 | 0.80 (0.49–1.31) | 21 | 1.25 (0.72–2.17) | 4 | — | 84 | 0.91 (0.63–1.31) | 26 | 0.87 (0.53–1.45) |
| P for trend | 0.50 | 0.60 | 0.39 | 0.66 | 0.48 | ||||||||
| RXR-β G392T (rs2744537) | |||||||||||||
| GG | 720 | 676 | 539 | 221 | 1.00 | 118 | 1.00 | 44 | 1.00 | 603 | 1.00 | 199 | 1.00 |
| TG + TTb | 56 | 52 | 45 | 14 | 0.82 (0.45–1.52) | 7 | 0.76 (0.34–1.72) | 2 | — | 59 | 1.21 (0.80–1.82) | 17 | 1.01 (0.56–1.81) |
| P for trend | 0.53 | 0.51 | — | 0.37 | 0.98 | ||||||||
| RXR-β C51T (rs2076310) | |||||||||||||
| CC | 331 | 303 | 234 | 97 | 1.00 | 53 | 1.00 | 22 | 1.00 | 255 | 1.00 | 93 | 1.00 |
| TC | 353 | 339 | 284 | 101 | 0.94 (0.68–1.29) | 47 | 0.84 (0.55–1.27) | 21 | 0.92 (0.50–1.71) | 313 | 0.98 (0.77–1.25) | 92 | 0.82 (0.58–1.14) |
| TT | 93 | 86 | 67 | 36 | 1.30 (0.83–2.04) | 25 | 1.67 (0.99–2.84) | 3 | 0.47 (0.14–1.60) | 94 | 1.28 (0.89–1.85) | 32 | 1.20 (0.74–1.95) |
| P for trend | 0.46 | 0.21 | 0.29 | 0.34 | 0.94 | ||||||||
| INS A–6T (rs689) | |||||||||||||
| AA | 698 | 658 | 528 | 214 | 1.00 | 116 | 1.00 | 43 | 1.00 | 603 | 1.00 | 200 | 1.00 |
| TA + TTb | 73 | 65 | 52 | 20 | 0.96 (0.57–1.62) | 7 | 0.57 (0.26–1.99) | 3 | — | 57 | 0.96 (0.64–1.44) | 15 | 0.79(0.43–1.44) |
| P for trend | 0.88 | 0.18 | — | 0.85 | 0.44 | ||||||||
| PPAR-γ C161T (rs3856806) | |||||||||||||
| CC | 457 | 428 | 350 | 127 | 1.00 | 74 | 1.00 | 27 | 1.00 | 411 | 1.00 | 135 | 1.00 |
| TC | 284 | 264 | 205 | 95 | 1.22 (0.89–1.65) | 44 | 0.96 (0.64–1.43) | 18 | 1.10 (0.60–2.04) | 226 | 0.92 (0.72–1.17) | 69 | 0.86 (0.62–1.21) |
| TT | 41 | 41 | 34 | 15 | 1.25 (0.67–2.33) | 8 | 1.21 (0.55–2.69) | 2 | — | 35 | 0.84 (0.51–1.39) | 17 | 1.26 (0.68–2.34) |
| P for trend | 0.21 | 0.88 | 0.93 | 0.36 | 0.97 | ||||||||
| PPAR-δ T15C (rs2016520) | |||||||||||||
| TT | 388 | 362 | 286 | 119 | 1.00 | 65 | 1.00 | 26 | 1.00 | 311 | 1.00 | 114 | 1.00 |
| TC | 267 | 253 | 209 | 81 | 0.98 (0.71–1.36) | 42 | 0.95 (0.63–1.45) | 16 | 0.76 (0.40–1.44)b | 224 | 0.96 (0.75–1.24) | 77 | 0.89 (0.63–1.26) |
| CC | 60 | 56 | 42 | 20 | 1.09 (0.63–1.89) | 10 | 1.00 (0.49–2.06) | 66 | 1.36 (0.89–2.08) | 12 | 0.72 (0.36–1.42) | ||
| P for trend | 0.87 | 0.90 | 0.14 | 0.40 | 0.29 | ||||||||
a
Bile duct cancer and ampullary cancer cases were compared with all population controls (N1), gallbladder cancer cases were compared with controls without cholecytectomy (N2), and gallbladder and bile duct stone were compared with controls without biliary stones (N3).
b
OR was calculated for homozygous and heterozygous variants combined due to rare homozygous variant carrier.